MedC Biopharma Partners With A2W Pharma To Develop Cannabinoid Therapeutics

MedC Biopharma entered into partnership with A2W Pharma of Malta in the development of MedC's proprietary novel cannabinoid formulations for the treatment of various cancer-related indications. A2W is a subsidiary of Amino Chemicals of Malta, which is a subsidiary of ABA Chemicals of China, a global pharmaceutical company.

MedC Biopharm is focused on cannabinoid drug therapeutics. MedC's methodology screens for combinations of synergetic cannabinoids in treating various medical indications. Skin cancers are MedC's primary targets. MedC has discovered …

Full story available on Benzinga.com

More MedC Biopharma Partners With A2W Pharma To Develop Cannabinoid Therapeutics